兰州大学学报（医学版）2018，Vol.44Issue(5)：9-15,7.DOI:10.13885/j.issn.1000-2812.2018.05.002
肺血管扩张剂治疗Fontan手术术后肺动脉高血压患者的疗效及安全性的系统评价及Meta分析
Efficacy and safety of pulmonary vasodilators in patients with pulmonary artery hybertension Fontan circulation: a Meta-analysis of randomizedcontrolled trials
摘要
Abstract
Objective No previous Meta-analysis has evaluated the efficacy and safety of pulmonary vasodilators in patients pulmonary artery hybertension (PAH) with Fontan procedure. Methods Relevant studies published were identified through a search of the PubMed, Embase, Cochrane databases and Clinical trial.gov Pooled outcomes were determined to assess the efficacy and safety of pulmonary vasodilators in Fontan patients. Results Nine randomized controlled studies involving 381 patients with Fontan circulation were included. Pulmonary vasodilator therapy led to significant reduction in the mean pulmonary artery pressure (mPAP) and to a significant improvement in New York Heart Association (NYHA) functional class.The 6-minute walk distance (6 MWD) was significantly increased, and the peak oxygen consumption (VO2) was also likewise improved in the pulmonary vasodilator group. No significant change was found in mortality and brain natriuretic peptide (BNP) or N-terminal B-type natriuretic peptide (NT-proBNP) levels. Four studies reported no side effects, but with good drug tolerance, and two studies reported mild adverse effects.Conclusion Pulmonary vasodilators, could evidently improve hemodynamic indicators, including mPAP and peak VO2, peak oxygen consumption.关键词
Fontan手术/5-磷酸二酯酶抑制剂/内皮素受体拮抗剂/有效性/安全性Key words
Fontan procedure/phosphodiesterase type 5 inhibitor/endothelin receptor antagonist/efficacy/safety分类
医药卫生引用本文复制引用
王吴婉,胡贤康,廖尉廷,曾小芳,封盼攀,黄玮..肺血管扩张剂治疗Fontan手术术后肺动脉高血压患者的疗效及安全性的系统评价及Meta分析[J].兰州大学学报（医学版）,2018,44(5):9-15,7.基金项目
国家自然科学基金项目(81170188 （）
30971212) （）
